[0001] The invention relates to a sanitising composition and in particular to a sanitising
composition which allows for an effective and non-toxic sanitising of products such
as
in-ovo injection equipment.
[0002] Automated
in-ovo injection systems enable the delivery of biological and pharmaceutical products directly
into chick embryos, whilst still in the egg. Such injection systems can typically
inoculate between 20,000 and 50,000 eggs per hour, eliminating the need to manually
inject chicks after they have hatched. Such systems improve productivity in the hatcheries,
and result in the production of healthier birds.
[0003] During the operation of the
in-ovo injection equipment, typically one hundred eggs are injected on each process occasion.
After each injection it is necessary to flush the lines, needles and the egg surfaces
with a suitable sanitiser, to prevent contamination by microbiological pathogens on
the surfaces of the equipment and eggs.
[0004] Existing procedures involve the use of a sanitiser such as sodium hypochlorite. However,
there are a number of serious disadvantages in the use of such a product and similar
products such as calcium hypochlorite. Hypochlorites are alkaline products having
a pH typically greater than pH8.5. At these high pH levels the product is toxic to
the chick embryo. It is therefore necessary to buffer the pH by adding an acid immediately
prior to use.
[0005] Currently the standard hand-mixed sanitiser solutions may consist of a mixture of
5% sodium hypochlorite diluted in water to give an operating solution strength of
0.5%. Separately, an acid solution is made up to buffer the 0.5% sodium hypochlorite
solution to lower the pH. For example citric acid may be dissolved in water and 5%
sodium hypochlorite added to the acid solution to give a final solution of 0.5% sodium
hypochlorite.
[0006] Such hand-mixed sanitising solutions are however unsatisfactory for reliably disinfecting
the
in-ovo equipment for a number of reasons.
[0007] Commercial hypochlorite products are available from 1% to over 10% available chlorine.
There are no standard solutions available. Because many of these products are used
for non-critical purposes (for example, for household uses), the strengths of the
products are inconsistent. It is also well known that hypochlorite products are unstable,
losing their potency in storage. Where the solution strength is not known with absolute
confidence it is necessary to chemically analyse the hypochlorite products to determine
the precise strength of the product before making up sanitiser solutions which are
used for critical purposes such as sanitising
in ovo equipment.
[0008] In addition, when buffered to the desirable pH with a suitable acid, the resultant
sanitiser solution is highly unstable, losing about 30% of its strength in one day
and up to 70% of its strength in two days.
[0009] The procedure for making up the
in-ovo sanitising solutions using commercial hypochlorite products is also complex, time-consuming
and is prone to costly mistakes and errors, leading to potential pathogenic contamination
of the eggs and embryos.
[0010] There is therefore a need for an improved stable sanitiser composition which is effective,
in particular for sanitising equipment, especially
in ovo injection equipment in a non-toxic and efficient manner.
[0011] US-A-5,114,647 describes an effervescent tablet formulation comprising a sanitising
agent and sodium carbonate, adipic acid, sodium bicarbonate. GB-A-2,242,130, CH-A-527,124,
GB-A-1,505,738, JP-A-55,047,248, FR-A-2,575,637 and EPO 230133 also describe sanitising
compositions.
Statements of Invention
[0012] According to the invention there is provided a water soluble sanitising tablet comprising
a chlorinated isocyanurate and an effervescent base, the effervescent base comprising
sodium carbonate, adipic acid and sodium bicarbonate characterised in that the tablet
does not contain tabletting aids and in that the sodium carbonate, adipic acid and
sodium bicarbonate are present in an approximate weight ratio of 1:1:1 to provide
a sanitising solution having a pH of from 6.8 to 7.4.
[0013] The effervescent tablet format has the advantages of being in a unit dose format,
which self-dissolves in water, to produce sanitiser solutions of known and accurate
strength, without having to weigh out powders, measure out liquids and to compute
the required dosage and solution strength. Tablets are easier and safer to handle
and store, and they do not spill.
[0014] Most preferably the ratio is approximately 20:19:19. These ratios surprisingly produce
good quality effervescent tablets with controlled release of solutions of a narrow
band of pH values over a time period, and with stable release of available chlorine
over a time period.
[0015] The particular advantages of utilising sodium bicarbonate are that it is very soluble
in water, it is suitable for use in effervescent preparations, it is available in
pharmaceutical or food grade and produces alkaline solutions.
[0016] Adipic acid has the advantage of being non hygroscopic, which helps to preserve the
integrity and stability of the finished formulation, and also the material has lubricating
properties that aid the tabletting process.
[0017] Preferably the chlorinated isocyanurate is sodium dichloroisocyanurate. Sodium dichloroisocyanurate
is readily soluble in water, producing solutions that are effective sanitisers and,
more particularly in relation to this invention, remain active over a wide range of
pH.
[0018] The sodium carbonate buffering agent is an admixture of sodium carbonate in a granular
form and sodium carbonate in a powder form. Sodium carbonate is readily soluble in
water, is available in pharmaceutical or food grades and is strongly alkaline.
[0019] The weight ratio of granular sodium carbonate to powder sodium carbonate is between
60:40 and 90:10. The choice of the particular admixture of granular and powder materials
enables the production of a stable effervescent tablet of acceptable disintegration
characteristics, whilst retaining the opportunity for processing by direct compression.
[0020] The composition of the invention preferably delivers approximately 0.5% available
chlorine. A 0.5% available chlorine solution has the wide-spectrum activity necessary
for effective sanitation, being effective against spores, viruses, mycobacteria, bacteria
and fungi.
[0021] The composition is preferably formed by a direct compression technique, which enables
the manufacture of the alkali effervescent tablets without pre-processing by granulation
and drying of the ingredients or addition of tabletting aids.
[0022] The invention also provides a non-therapeutic method for sanitising comprising the
single step of dissolving a tablet of the invention in water and flushing, immersing
or dipping product to be sanitised in the sanitising solution. Preferably the composition
is in a water soluble tablet form. The product may be eggs or
in ovo injection equipment.
[0023] The invention further provides a method for sanitising
in-ovo injection equipment comprising the single step of dissolving a tablet of the invention
in water to form a sanitising solution. The sanitising solution is then flushed through
the lines and needles and over the egg surfaces prior to each
in-ovo injection. Preferably the sanitising solution comprises a chlorinated isocyanurate.
[0024] The invention also provides a method for sanitising eggs comprising dissolving a
tablet of the invention in water to form a sanitising solution and flushing, immersing
or dipping the eggs in the sanitising solution.
[0025] Unlike many preparations known in the art, the selection of the ingredients surprisingly
forms a tablet with desirable physical characteristics without recourse to pre-preparation
of the ingredients by agglomeration and combination with wetting agents (such as water
or isopropyl alcohol), which subsequently requires drying (such as with a fluid bed
dryer), and/or compacting and/or granulating, and without the addition of tabletting
aids (such as sorbitol, salts of stearates, salts of lauryl sulphate, Emcosoy, polyetheylene
glycol, sodium benzoate and similar).
Brief description of the drawings
[0026] The invention will be more clearly understood from the following description of some
embodiments thereof, given by way of example only with reference to the accompanying
drawings in which:-
Fig. 1 is a graph showing the change in pH over time (hours) for a hand mixed solution
in comparison to effervescent tablets of the invention; and
Fig. 2 is a graph showing the stability (mg/l chlorine) of a hand mixed solution in
comparison to effervescent tablets of the invention.
Detailed Description
[0027] Chlorinated isocyanurates are well known chlorine donors used as swimming pool disinfectants
and in formulations used for dishwashing, laundry products or disinfection of baby
feeding bottles.
[0028] Of the chlorinated isocyanurates available, the most suitable are those with the
greatest solubility, such as sodium or potassium dichloroisocyanurate.
[0029] The present invention provides a water soluble composition comprising a chlorinated
isocyanurate and an alkali buffering effervescent base, which provides a non-toxic
solution having a pH from between 6.8 and 7.4. This is a pH range that is compatible
with the embryotic fluid or air sac of a poultry egg. The composition may be used
in sanitising equipment, in particular for sanitising
in ovo injection equipment. The composition is very stable in solution and simple to use.
[0030] The composition of the invention may be produced in a solid dose form. A solid dose
form eliminates the necessity to weigh out a quantity of powder or granules each time
a sanitiser solution is required. Using a single solid dose form also ensures that
a sanitising solution having an accurate and known disinfectant concentration is produced
in a one step process. The handling of a solid dose form is also easier and safer
than handling chlorinated powders or granules or hypochlorite solutions.
[0031] The composition may be in the form of tablets especially effervescent tablets. Effervescent
tablets are preferred because they disperse quickly in solution and dissolve the active
ingredient. There is no need to crush the tablets and/or stir the solutions to achieve
a clear sanitising solution within a reasonable time period.
[0032] The effervescent tablets comprise an active ingredient such as a chlorinated isocyanurate
and an inert, effervescent base. The inert, effervescent base typically comprises
an aliphatic carboxylic acid or salt thereof such as fumaric acid or adipic acid and
an alkali metal carbonate or bicarbonate such as sodium bicarbonate.
[0033] However, effervescent tablets from such a typical formulation producing a sanitiser
solution of approximately 0.5% available chlorine strength, produce solutions with
a pH of approximately 5.5 to 6.5, and typically approximately pH6.0. Such pH values
are too acidic and are toxic to chick embryos.
[0034] To achieve a pH which is compatible and non-toxic to the embryotic fluid or air sac
of a chick egg the effervescent tablets include a buffering agent to increase the
pH to approximately pH 7.0. The formulation to include a buffering agent in accordance
with this invention does not inhibit the tableting quality and the composition remains
easy to compress into tablet form by a direct compression process. The tablet disintegrates
in solution within reasonable time producing a clear working solution. Most importantly
the addition of the buffering agent does not inhibit the disinfection capability of
the sanitising solution.
[0035] Buffering agents of choice must be non-toxic, readily soluble, non-oxidisable and
commercially available. Examples suitable for use in the present invention include
sodium or potassium hydroxide, sodium tripolyphosphate, trisodium phosphate, sodium
carbonate, and the ortho- and metasilicates.
[0036] It was found that the use of powdered sodium carbonate in total produces a tablet
of poor physical quality. Similarly, a formulation using granular sodium carbonate
also produced a tablet of poor physical qualities. The term granular in the specification
is taken to encompass compounds having a granular grade giving a typical sieve analysis
of:
| Micron |
% Retained |
| 2800 |
1.5% |
| 425 |
28.3% |
| 250 |
44.9% |
| 125 |
22.0% |
| 63 |
2.0% |
| |
QS |
[0037] It was surprisingly found that an admixture containing both granular and powder sodium
carbonate produced a tablet of good physical characteristics by a direct compression
process and without the addition of the usual tabletting aids. An admixture where
the ratio of granular sodium carbonate to powder sodium carbonate is between 60:40
and 90:10 produced a tablet of excellent physical characteristics.
[0038] Tablets prepared using such an admixture of sodium carbonate have been shown to have
good disintegration properties, produce clear sanitising solutions and are stable
at normal atmospheric conditions.
[0039] A critical factor of stabilisation is the pH of the sanitising solution so prepared.
Without stable control of the pH in parallel with the desired target pH of the embryotic
fluid or air sac, toxic reactions may result in poor hatchability of the chicks from
the eggs. The following results demonstrate the remarkable pH control of the current
invention, compared especially to the current hand-mixed method when using sodium
hypochlorite liquid, buffered with citric acid.
[0040] The pH of the Hand Mixed solution started at pH9 reducing to pH8.6 after 6 hours,
where it stabilised over the balance of the 24 hour period (Fig. 1). The effervescent
tablet of the current invention commenced with a pH of 7.16 rising to 7.18 after 8
hours and reducing to 7.05 after 24 hours. The tablet had a stabilised pH in the range
of 7 to 7.2, which is ideally compatible with the egg air sac - thus protecting against
potential toxicity problems and, therefore, assisting the maximisation of hatchability.
[0041] The choice of the sodium carbonate also significantly contributes to the effervescent
nature of the formulation.
[0042] It is also envisaged that the composition of the invention may be prepared in other
solid dose forms, for example in particulate form sealed within a sachet which dissolves
in a known volume of water to provide a known concentration of sanitising solution.
[0043] The invention will be more clearly understood from the following description given
by way of example.
Example 1
[0044] Tablets are prepared having the following formulation by weight. The formulation
given is for a single tablet.
| Sodium dichloroisocyanurate |
42% |
| Sodium bicarbonate |
19% |
| Adipic acid |
19% |
| Sodium carbonate |
20% |
[0045] 8.15g sodium dichloroisocyanurate, 3.75g sodium bicarbonate, 3.59g adipic acid and
3.76g of sodium carbonate are weighed out and dry blended together. The dry blend
is then compressed by direct compression (on chrome plated tooling) into tablets.
Example 2
[0046] The hatchability of live embryos transferred was measured in approximately 50-egg
replicates per trial per treatment. Two identical trials were conducted. Eggs were
either not injected or were air cell injected with either 30 or 300µl volume, using
a hand-mixed sanitiser composition (comprising per litre of water: 106mg sodium bromide,
1.19grams citric acid and 106ml of 5.5% hypochlorite), an effervescent tablet of Example
1 and saline. The chicks (n=108) were grown out in brooder batteries for one week
and monitored for mortality. With the exception of the non-injected controls, the
treatment combinations were appropriate for a two-way factorial analysis in which
material and volume were both evaluated. The two-way factorial analysis was then conducted
using the previous trial as a blocking factor. Table 1(a) and (b) illustrate the results
of hatchability and late embryotic mortality results in the two identical trials.
Table 2 contains the results pooled across both trials. Results are shown for live
and late dead hatch, live pip and dead pip. (Pip refers to a bird that has not completely
emerged from the shell).
[0047] The hatchability results are based on necropsy of hatch residue.
[0048] The results show no significant interactions.
Table 1(a)
| Trial 1 |
Hatch of live |
Late Dead |
Live Pip |
Dead Pip |
| Not Inj. |
None |
Mean |
96.94 |
0.52 |
0.51 |
0.51 |
| |
|
SD |
3.53 |
1.04 |
1.02 |
1.02 |
| |
|
n |
4 |
4 |
4 |
4 |
| Std. Hand |
30µl |
Mean |
97.37 |
0.00 |
1.58 |
0.00 |
| Mix |
|
|
|
|
|
|
| |
|
SD |
3.14 |
0.00 |
2.03 |
0.00 |
| |
|
n |
4 |
4 |
4 |
4 |
| |
300µl |
Mean |
96.84 |
1.02 |
1.06 |
0.00 |
| |
|
SD |
1.22 |
2.04 |
1.22 |
0.00 |
| |
|
n |
4 |
4 |
4 |
4 |
| Effervescent |
30µl |
Mean |
95.23 |
0.00 |
2.11 |
0.00 |
| Tablets |
|
|
|
|
|
|
| |
|
SD |
2.68 |
0.00 |
1.70 |
0.00 |
| |
|
n |
4 |
4 |
4 |
4 |
| |
300µl |
Mean |
98.90 |
0.00 |
0.56 |
0.54 |
| |
|
SD |
1.27 |
0.00 |
1.11 |
1.09 |
| |
|
n |
4 |
4 |
4 |
4 |
| Saline |
30µl |
Mean |
94.80 |
2.04 |
1.01 |
1.53 |
| |
|
SD |
3.54 |
1.67 |
1.17 |
1.02 |
| |
|
n |
4 |
4 |
4 |
4 |
| |
300µl |
Mean |
96.80 |
1.12 |
1.56 |
0.52 |
| |
|
SD |
3.58 |
1.29 |
1.99 |
1.04 |
| |
|
n |
4 |
4 |
4 |
4 |
Table 1(b)
| Trial 2 |
Hatch of live |
Late Dead |
Live Pip |
Dead Pip |
| Not Inj. |
None |
Mean |
97.99 |
1.00 |
0.50 |
0.51 |
| |
|
SD |
1.63 |
1.15 |
1.00 |
1.02 |
| |
|
n |
4 |
4 |
4 |
4 |
| Std. Hand |
30µl |
Mean |
97.44 |
0.52 |
0.50 |
0.00 |
| Mix |
|
|
|
|
|
|
| |
|
SD |
3.10 |
1.04 |
1.00 |
0.00 |
| |
|
n |
4 |
4 |
4 |
4 |
| |
300µl |
Mean |
98.00 |
0.00 |
1.00 |
0.00 |
| |
|
SD |
4.00 |
0.00 |
2.00 |
0.00 |
| |
|
n |
4 |
4 |
4 |
4 |
| Effervescent |
30µl |
Mean |
97.41 |
2.08 |
0.00 |
0.51 |
| Tablets |
|
|
|
|
|
|
| |
|
SD |
0.99 |
0.04 |
0.00 |
1.02 |
| |
|
n |
4 |
4 |
4 |
4 |
| |
300µl |
Mean |
98.98 |
1.02 |
0.00 |
0.00 |
| |
|
SD |
2.04 |
2.04 |
0.00 |
0.00 |
| |
|
n |
4 |
4 |
4 |
4 |
| Saline |
30µl |
Mean |
98.50 |
0.00 |
0.00 |
1.00 |
| |
|
SD |
1.00 |
0.00 |
0.00 |
1.15 |
| |
|
n |
4 |
4 |
4 |
4 |
| |
300µl |
Mean |
98.49 |
0.00 |
0.50 |
1.01 |
| |
|
SD |
1.01 |
0.00 |
1.00 |
1.17 |
| |
|
n |
4 |
4 |
4 |
4 |
Table 2
| |
|
|
Hatch of live |
Late Dead |
Live Pip |
Dead Pip |
| Not Inj. |
None |
Mean |
97.46 |
0.76 |
0.51 |
0.51 |
| |
|
SD |
2.61 |
1.05 |
0.94 |
0.94 |
| |
|
n |
8 |
8 |
8 |
8 |
| Std. Hand |
30µl |
Mean |
97.41 |
0.26 |
1.04 |
0.00 |
| Mix |
|
|
|
|
|
|
| |
|
SD |
2.89 |
0.74 |
1.59 |
0.00 |
| |
|
n |
8 |
8 |
8 |
8 |
| |
300µl |
Mean |
97.42 |
0.51 |
1.03 |
0.00 |
| |
|
SD |
2.81 |
1.44 |
1.53 |
0.00 |
| |
|
n |
8 |
8 |
8 |
8 |
| Effervescent |
30µl |
Mean |
96.32 |
1.04 |
1.05 |
0.26 |
| Tablets |
|
|
|
|
|
|
| |
|
SD |
2.20 |
1.11 |
1.58 |
0.72 |
| |
|
n |
8 |
8 |
8 |
8 |
| |
300µl |
Mean |
98.94 |
0.51 |
0.28 |
0.27 |
| |
|
SD |
1.57 |
1.44 |
0.79 |
0.77 |
| |
|
n |
8 |
8 |
8 |
8 |
| Saline |
30µl |
Mean |
96.70 |
1.02 |
0.51 |
1.27 |
| |
|
SD |
3.08 |
1.54 |
0.94 |
1.05 |
| |
|
n |
8 |
8 |
8 |
8 |
| |
300µl |
Mean |
97.65 |
0.56 |
1.03 |
0.77 |
| |
|
SD |
2.60 |
1.04 |
1.57 |
1.06 |
| |
|
n |
8 |
8 |
8 |
8 |
[0049] Table 3 illustrates the results of early mortality by trial and Table 4 gives the
pooled results. There were no significant interactions or main material effects.
Table 3
| Trial 1 |
% Mortality |
| Not injected |
|
None |
3.70 |
| Std Hand Mix |
|
30µl |
0.93 |
| |
|
300µl |
0.93 |
| Effervescent Tablets |
|
30µl |
0.93 |
| |
|
300µl |
0.00 |
| Saline |
|
30µl |
2.78 |
| |
|
300µl |
0.00 |
| |
Trial 2 |
|
|
| Not injected |
|
None |
0.93 |
| Standard Hand Mix |
|
30µl |
1.85 |
| |
|
300µl |
0.00 |
| Effervescent Tablets |
|
30µl |
2.78 |
| |
|
300µl |
0.00 |
| Saline |
|
30µl |
4.63 |
| |
|
300µl |
0.00 |
Table 4
| |
% Mortality |
| Not injected |
None |
2.31 |
| Std Hand Mix |
30µl |
1.39 |
| |
300µl |
0.46 |
| Effervescent Tablets |
30µl |
1.85 |
| |
300µl |
0.00 |
| Saline |
30µl |
3.70 |
| |
300µl |
0.00 |
[0050] The stability of the sanitising solutions is also a critical factor in maintaining
efficacy over the cycle of use of the egg injection equipment. The stability of the
formulated tablets showed excellent characteristics, especially when compared to the
standard hand-mixed product, hereinbefore described.
[0051] Figs. 3 and 4 show the stability of solutions over time. The standard Hand Mixed
solution (Fig. 2) gave an initial concentration of 4,600 mg/l chlorine, which reduced
to 3000 mg/l in less than 10 hours - a 35% drop. The solution had lost almost 20%
of its strength after just 4 hours. Such losses could give rise to concerns with the
efficacy of the product during the egg injection cycle. The effervescent tablet of
the current invention gave a solution initial strength of almost 5,300 mg/1 chlorine
retaining a level of over 4,900mg/l after 24 hours, with no significant change in
strength over the initial 8 hours, giving an exceptional performance.
[0052] A study was also carried out to determine the stability of an approximate 0.5% available
chlorine solution using the effervescent tablet of Example 1 over a 9 week period.
As table 5 illustrates the solution maintained a stable pH over the 9 weeks.
Table 5
| Time (Weeks) |
Available Chlorine (ppm) |
pH |
Temperature (°C) |
| 0 |
4843.9 |
6.89 |
15 |
| 1 |
4434.56 |
6.96 |
14 |
| 2 |
3572.32 |
6.97 |
16 |
| 3 |
3615.87 |
6.97 |
16 |
| 4 |
3342.97 |
6.94 |
17 |
| 5 |
3070.08 |
6.93 |
18 |
| 6 |
2933.63 |
6.89 |
16 |
| 7 |
2387.84 |
7.05 |
18 |
| 8 |
2319.62 |
6.98 |
17 |
| 9 |
2046.72 |
6.95 |
18 |
1. A water soluble sanitising tablet comprising a chlorinated isocyanurate and an effervescent
base, the effervescent base comprising sodium carbonate, adipic acid and sodium bicarbonate
characterised in that the tablet does not contain tabletting aids and in that the sodium carbonate, adipic acid and sodium bicarbonate are present in an approximate
weight ratio of 1:1:1 to provide a sanitising solution having a pH of from 6.8 to
7.4 and wherein the sodium carbonate buffering agent is an admixture of sodium carbonate
in a granular form and sodium carbonate in a powder form, the weight ratio of granular
sodium carbonate to powder sodium carbonate being between 60:40 and 90:10.
2. A tablet as claimed in claim 1 wherein the weight ratio sodium carbonate, adipic acid
and sodium bicarbonate is approximately 20:19:19.
3. A tablet as claimed in any of claims 1 to 2 wherein the sanitising solution has a
pH of approximately 7.0.
4. A tablet as claimed in any of claims 1 to 3 wherein the chlorinated isocyanurate is
sodium dichloroisocyanurate.
5. A tablet as claimed in any preceding claim wherein the tablet delivers approximately
0.5% available chlorine.
6. A tablet as claimed in any of claims 1 to 5 wherein the tablet is formed by a direct
compression technique.
7. A non-therapeutic method for sanitising comprising the steps of dissolving a tablet
as claimed in any of claims 1 to 6 in water to form a sanitising solution and flushing,
immersing or dipping a product to be sanitised in the sanitising solution.
8. A method as claimed in claim 7 wherein the product is in ovo injection equipment,
9. A method as claimed in claim 7 wherein the product is an egg.
10. A method for sanitising in-ovo injection equipment comprising the step of dissolving a tablet as claimed in any
of claims 1 to 6 in water to form a sanitising solution and flushing in-ovo injection equipment with the sanitising solution prior to each in ovo injection.
11. A method for sanitising eggs comprising dissolving a tablet as claimed in any of claims
1 to 6 in water to form a sanitising solution and flushing, immersing or dipping the
eggs in the sanitising solution.
1. Wasserlösliche Tablette zur Desinfektion, umfassend ein chloriertes Isocyanurat und
eine Efferveszenzgrundlage, wobei die Efferveszenzgrundlage Natriumcarbonat, Adipinsäure
und Natriumbicarbonat umfasst, dadurch gekennzeichnet, dass die Tablette keine Tablettierhilfsmittel enthält und dass das Natriumcarbonat, die
Adipinsäure und das Natriumbicarbonat in einem annähernden Gewichtsverhältnis von
1:1:1 zur Bereitstellung einer Desinfektionslösung mit einem pH von 6,8 bis 7,4 anwesend
sind und worin das Natriumcarbonat-Puffermittel eine Beimischung aus Natriumcarbonat
in einer Granulatform und Natriumcarbonat in einer Pulverform darstellt, wobei das
Gewichtsverhältnis von Natriumcarbonat-Granulat zu Natriumcarbonat-Pulver zwischen
60:40 und 90:10 liegt.
2. Tablette nach Anspruch 1, worin das Gewichtsverhältnis von Natriumcarbonat, Adipinsäure
und Natriumbicarbonat bei ca. 20:19:19 liegt.
3. Tablette nach einem der Ansprüche 1 bis 2, worin die Desinfektionslösung einen pH
von ca. 7,0 aufweist.
4. Tablette nach einem der Ansprüche 1 bis 3, worin das chlorierte Isocyanurat Natriumdichlorisocyanurat
darstellt.
5. Tablette nach einem der vorangehenden Ansprüche, worin die Tablette ca. 0,5 % verfügbares
Chlor abgibt.
6. Tablette nach einem der Ansprüche 1 bis 5, worin die Tablette durch ein direktes Kompressionsverfahren
geformt wird.
7. Nicht therapeutisches Verfahren zum Desinfizieren, umfassend die Schritte des Auflösens
einer Tablette nach einem der Ansprüche 1 bis 6 in Wasser zur Bildung einer Desinfektionslösung
und Spülen, Unter- oder Eintauchen eines zu desinfizierenden Produktes in die Desinfektionslösung.
8. Verfahren nach Anspruch 7, worin das Produkt ein in ovo-Injektionsgerät darstellt.
9. Verfahren nach Anspruch 7, worin das Produkt ein Ei darstellt.
10. Verfahren zum Desinfizieren eines in ovo-Injektionsgeräts, umfassend den Schritt des
Auflösens einer Tablette nach einem der Ansprüche 1 bis 6 in Wasser zur Bildung einer
Desinfektionslösung und Spülen des in ovo-Injektionsgeräts mit der Desinfektionslösung
vor jeder in ovo-Injektion.
11. Verfahren zum Desinfizieren von Eiern, umfassend das Auflösen einer Tablette nach
einem der Ansprüche 1 bis 6 in Wasser zur Bildung einer Desinfektionslösung und Spülen,
Unter- oder Eintauchen der Eier in die Desinfektionslösung.
1. Pastille désinfectante soluble dans l'eau comprenant un isocyanurate chloré et une
base effervescente, la base effervescente comprenant du carbonate de sodium, de l'acide
adipique et du bicarbonate de sodium caractérisée en ce que la pastille ne contient pas d'agent facilitant le pastillage et en ce que le carbonate de sodium, l'acide adipique et le bicarbonate de sodium sont présents
en un rapport massique approximatif de 1:1:1 pour produire une solution désinfectante
ayant un pH allant de 6,8 à 7,4 et dans laquelle l'agent tampon de carbonate de sodium
est un mélange de carbonate de sodium sous forme granulaire et de carbonate de sodium
sous forme pulvérulente, le rapport massique de carbonate de sodium granulaire sur
le carbonate de sodium en poudre étant compris entre 60:40 et 90:10.
2. Pastille selon la revendication 1, dans laquelle le rapport massique du carbonate
de sodium sur l'acide adipique sur le bicarbonate de sodium est égal à approximativement
20:19:19.
3. Pastille selon l'une quelconque des revendications 1 à 2, dans laquelle la solution
désinfectante a un pH d'approximativement 7,0.
4. Pastille selon l'une quelconque des revendications 1 à 3, dans laquelle l'isocyanurate
chloré est le dichloroisocyanurate de sodium.
5. Pastille selon l'une quelconque des revendications précédentes, dans laquelle la pastille
délivre approximativement 0,5 % du chlore disponible.
6. Pastille selon l'une quelconque des revendications 1 à 5, dans laquelle la pastille
est formée par une technique de compression directe.
7. Procédé non thérapeutique de désinfection comprenant les étapes consistant à dissoudre
une pastille selon l'une quelconque des revendications 1 à 6 dans de l'eau pour former
une solution désinfectante et à rincer, immerger ou tremper un produit à désinfecter
dans la solution désinfectante.
8. Procédé selon la revendication 7, dans laquelle le produit est un équipement d'injection
in ovo.
9. Procédé selon la revendication 7 dans laquelle le produit est un oeuf.
10. Procédé de désinfection d'un équipement d'injection in ovo comprenant l'étape consistant à dissoudre une pastille selon l'une quelconque des
revendications 1 à 6 dans de l'eau pour former une solution désinfectante et à rincer
l'équipement d'injection in ovo avec la solution désinfectante avant chaque injection in ovo.
11. Procédé pour désinfecter des oeufs comprenant les étapes consistant à dissoudre une
pastille selon l'une quelconque des revendications 1 à 6 dans de l'eau pour former
une solution désinfectante et à rincer, immerger ou tremper les oeufs dans la solution
désinfectante.